You are here: Industry Insights > Duchenne Muscular Dystrophy

News List

Solid Biosciences to Present at Upcoming Scientific Conferences firstwordpharma
May 26, 2021
Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that the Company will participate at the following upcoming scientific conferences
Antisense ATL1102 final phase 2 DMD results meet primary endpoint and exceed expectations on seconda pharmaceutical-business-review
May 27, 2020
Antisense Therapeutics is pleased to advise that the Phase II clinical trial of ANP’s immunomodulatory therapy, ATL1102 for Duchenne Muscular Dystrophy (DMD) has met its primary endpoint ...
New drug for Duchenne muscular dystrophy clears phase 1 clinical trial worldpharmanews
February 22, 2019
Patients with Duchenne muscular dystrophy (DMD) have few treatment options.
ICER Posts Draft Scoping Document for the Assessment of Treatments for Duchenne Muscular Dystrophy firstwordpharma
January 13, 2019
The Institute for Clinical and Economic Review (ICER) has posted a Draft Scoping Document outlining a planned review of the comparative clinical effectiveness and value of treatments for Duchenne muscular dystrophy (DMD).
Celecoxib shows potential benefit for Duchenne muscular dystrophy europeanpharmaceuticalreview
May 09, 2018
Researchers have found that the FDA-approved anti-inflammatory drug Celecoxib had beneficial effects on the muscle function in muscular dystrophy…
FDA Approves Emflaza drugs.com
February 10, 2017
FDA Approves Emflaza (deflazacort) to treat Duchenne Muscular Dystrophy